Search company, investor...

ErgoNex Pharma

ergonex.com

Founded Year

2004

Stage

Series B | Dead

Total Raised

$6.74M

Last Raised

$50K

About ErgoNex Pharma

Provider of products for novel and typically underserved indications. The company focused on the clinical development and commercialization of terguride for the treatment of distinct orphan diseases. It also identifies and develops therapeutic use of existing drugs in new disease areas.

Headquarters Location

Rütistrasse 20

Appenzell, CH-9050,

Switzerland

41 71 788 40 65

Missing: ErgoNex Pharma's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: ErgoNex Pharma's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

ErgoNex Pharma Frequently Asked Questions (FAQ)

  • When was ErgoNex Pharma founded?

    ErgoNex Pharma was founded in 2004.

  • Where is ErgoNex Pharma's headquarters?

    ErgoNex Pharma's headquarters is located at Rütistrasse 20, Appenzell.

  • What is ErgoNex Pharma's latest funding round?

    ErgoNex Pharma's latest funding round is Series B.

  • How much did ErgoNex Pharma raise?

    ErgoNex Pharma raised a total of $6.74M.

  • Who are the investors of ErgoNex Pharma?

    Investors of ErgoNex Pharma include High Tech Private Equity.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.